| Literature DB >> 32847571 |
Lisa Martinsson1, Staffan Lundström2,3, Johan Sundelöf4.
Abstract
BACKGROUND: Hospitalisation of patients with advanced dementia is generally regarded as less preferable compared to care at home or in a nursing home. For patients with other diagnoses, young age has been associated with better end-of-life care. However, studies comparing the quality of palliative care for persons with advanced dementia in hospitals and nursing homes are scarce. The aim of this study was to investigate whether quality of end-of-life care for patients with dementia depends on age, gender and place of death.Entities:
Keywords: Advanced dementia; Age differences; Dementia; End-of-life care; Gender; Hospitalisation; Palliative care; Place of care
Mesh:
Year: 2020 PMID: 32847571 PMCID: PMC7449048 DOI: 10.1186/s12904-020-00639-5
Source DB: PubMed Journal: BMC Palliat Care ISSN: 1472-684X Impact factor: 3.234
Numbers and proportions of death at hospital per age and gender category, and likelihoods of death at hospital compared to nursing home, depending on age group and gender. Odds ratios (OR) with 95% confidence intervals (CI) and p-values are reported
| Hospital deaths/all deaths (n) | Hospital deaths/all deaths (%) | OR | 95% CI | ||
|---|---|---|---|---|---|
| Age groups in years | |||||
| 41–64 | 8/95 | 8.4 | 1.436 | 0.688–2.995 | 0.335 |
| 65–84 | 418/5112 | 8.2 | 1.528 | 1.335–1.748 | < 0.001 |
| 85–110 | 541/11,255 | 4.8 | Refa | ||
| Gender | |||||
| Women | 432/11,120 | 3.9 | 0.387 | 0.338–0.442 | < 0.001 |
| Men | 535/5342 | 10.0 | Refa | ||
a Reference
End-of-life care outcomes for 13 quality indicators in hospitals and nursing homes. Differences in proportions between hospitals and nursing homes are calculated with chi-square test
| Quality indicators | Missing (n) | Hospital | Nursing home | |||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| Specialised palliative care team consulted | 0 | 22/967 | 2.3 | 192/15,495 | 1.2 | 0.006 |
| Documented decision to shift to end-of-life care | 1754 | 731/897 | 81.5 | 12,460/13,811 | 90.2 | < 0.001 |
| Next of kin given information about transition to end-of-life care | 1284 | 714/878 | 81.3 | 10,215/14,300 | 71.4 | < 0.001 |
| Next of kin offered a follow-up talk after death of the patient | 2968 | 263/617 | 42.6 | 9697/12,877 | 75.3 | < 0.001 |
| Pain assessed and documented during the last week of life | 619 | 140/861 | 16.3 | 4838/14,982 | 32.3 | < 0.001 |
| Symptoms other than pain assessed during the last week of life | 853 | 79/802 | 9.9 | 2773/14,807 | 18.7 | < 0.001 |
| Oral health assessed during the last week of life | 1280 | 630/824 | 76.5 | 10,992/14,358 | 76.6 | 0.947 |
| Prescription of PRN drugs against pain | 62 | 839/949 | 88.4 | 14,461/15,451 | 93.6 | < 0.001 |
| Prescription of PRN drugs against nausea | 225 | 398/927 | 42.9 | 9606/15,310 | 62.7 | < 0.001 |
| Prescription of PRN drugs against anxiety | 133 | 705/939 | 75.1 | 13,171/15,390 | 85.6 | < 0.001 |
| Pressure ulcer at death | 157 | 219/908 | 24.1 | 2278/15,397 | 14.8 | < 0.001 |
| Someone present at the moment of death | 291 | 652/936 | 69.7 | 13,711/15,235 | 90.0 | < 0.001 |
| Fluids via enteral tube or intravenously during last 24 h of life | 55 | 344/943 | 36.5 | 220/15,464 | 1.4 | < 0.001 |
Logistic regression model comparing 12 end-of-life care outcomes for three age groups (in years) and for men and women, adjusted for place of death (hospital/nursing home). Odds ratios (OR) and 95% confidence intervals (CI) are reported
| n | % | OR | 95% CI | ||
|---|---|---|---|---|---|
| PRN drugs against pain | |||||
| Age | |||||
| 41–64 | 88/95 | 92.6 | 1.006 | 0.464–2.185 | 0.987 |
| 65–84 | 4799/5086 | 94.4 | 1.335 | 1.159–1.537 | < 0.001 |
| 85–110 | 10,413/11,219 | 92.8 | Refa | ||
| Gender | |||||
| Women | 10,342/11,081 | 93.3 | 1.006 | 0.880–1.149 | 0.931 |
| Men | 4958/5319 | 93.2 | Refa | ||
| PRN drugs against nausea | |||||
| Age | |||||
| 41–64 | 59/94 | 62.8 | 1.108 | 0.726–1.691 | 0.636 |
| 65–84 | 3131/5037 | 62.2 | 1.069 | 0.997–1.147 | 0.060 |
| 85–110 | 6814/11,106 | 61.4 | Refa | ||
| Gender | |||||
| Women | 6832/10,984 | 62.2 | 1.038 | 0.969–1.113 | 0.285 |
| Men | 3172/5253 | 60.4 | Refa | ||
| PRN drugs against anxiety | |||||
| Age | |||||
| 41–64 | 79/94 | 84.0 | 0.991 | 0.568–1.730 | 0.975 |
| 65–84 | 4342/5063 | 85.8 | 1.127 | 1.024–1.240 | 0.014 |
| 85–110 | 9455/11,172 | 84.6 | Refa | ||
| Gender | |||||
| Women | 9405/11,041 | 85.2 | 1.017 | 0.926–1.116 | 0.728 |
| Men | 4471/5288 | 84.5 | Refa | ||
| Pain assessed and documented during the last week of life | |||||
| Age | |||||
| 41–64 | 29/93 | 31.2 | 1.025 | 0.658–1.595 | 0.914 |
| 65–84 | 1550/4916 | 31.5 | 1.039 | 0.965–1.118 | 0.313 |
| 85–110 | 3399/10,834 | 31.4 | Refa | ||
| Gender | |||||
| Women | 3428/10,726 | 32.0 | 1.042 | 0.968–1.121 | 0.277 |
| Men | 1550/5117 | 30.3 | Refa | ||
| Symptoms other than pain assessed during the last week of life | |||||
| Age | |||||
| 41–64 | 22/87 | 25.3 | 1.572 | 0.966–2.560 | 0.069 |
| 65–84 | 890/4830 | 18.4 | 1.049 | 0.960–1.146 | 0.294 |
| 85–110 | 1940/10,692 | 18.1 | Refa | ||
| Gender | |||||
| Women | 1984/10,584 | 18.7 | 1.080 | 0.988–1.181 | 0.091 |
| Men | 868/5025 | 17.3 | Refa | ||
| Oral health assessed during the last week of life | |||||
| Age | |||||
| 41–64 | 78/93 | 83.9 | 1.712 | 0.983–2.981 | 0.058 |
| 65–84 | 3696/4730 | 78.1 | 1.162 | 1.069–1.263 | < 0.001 |
| 85–110 | 7848/10,359 | 75.8 | Refa | ||
| Gender | |||||
| Women | 7923/10,286 | 77.0 | 1.112 | 1.025–1.206 | 0.010 |
| Men | 3699/4896 | 75.6 | Refa | ||
| Next of kin informed about transition to end-of-life care | |||||
| Age | |||||
| 41–64 | 72/90 | 80.0 | 1.630 | 0.970–2.739 | 0.065 |
| 65–84 | 3549/4733 | 75.0 | 1.224 | 1.131–1.325 | < 0.001 |
| 85–110 | 7308/10,355 | 70.6 | Refa | ||
| Gender | |||||
| Women | 7331/10,274 | 71.4 | 0.959 | 0.887–1.036 | 0.289 |
| Men | 3598/4904 | 73.4 | Refa | ||
| Next of kin offered a follow-up talk after death of the patient | |||||
| Age | |||||
| 41–64 | 69/84 | 82.1 | 1.776 | 1.005–3.140 | 0.048 |
| 65–84 | 3119/4152 | 75.1 | 1.161 | 1.064–1.265 | 0.001 |
| 85–110 | 6772/9258 | 73.1 | Refa | ||
| Gender | |||||
| Women | 6828/9217 | 74.1 | 0.983 | 0.903–1.071 | 0.701 |
| Men | 3132/4277 | 73.2 | Refa | ||
| Documented decision to shift to end-of-life care | |||||
| Age | |||||
| 41–64 | 75/84 | 89.3 | 1.066 | 0.531–2.141 | 0.858 |
| 65–84 | 4145/4574 | 90.6 | 1.216 | 1.079–1.371 | 0.001 |
| 85–110 | 8971/10,050 | 89.3 | Refa | ||
| Gender | |||||
| Women | 8934/9924 | 90.0 | 1.083 | 0.966–1.215 | 0.171 |
| Men | 4257/4784 | 89.0 | Refa | ||
| Specialised palliative care team consulted | |||||
| Age | |||||
| 41–64 | 3/95 | 3.2 | 2.895 | 0.902–9.293 | 0.074 |
| 65–84 | 84/5112 | 1.6 | 1.461 | 1.103–1.937 | 0.008 |
| 85–110 | 127/11,255 | 1.1 | Refa | ||
| Gender | |||||
| Women | 147/11,120 | 1.3 | 1.181 | 0.877–1.590 | 0.274 |
| Men | 67/5342 | 1.3 | Refa | ||
| Someone present at the moment of death | |||||
| Age | |||||
| 41–64 | 85/93 | 91.4 | 1.505 | 0.720–3.147 | 0.277 |
| 65–84 | 4554/5043 | 90.3 | 1.340 | 1.197–1.501 | < 0.001 |
| 85–110 | 9724/11,035 | 88.1 | Refa | ||
| Gender | |||||
| Women | 9691/10,915 | 88.8 | 0.904 | 0.811–1.008 | 0.070 |
| Men | 4672/5256 | 88.9 | Refa | ||
| Pressure ulcers at death | |||||
| Age | |||||
| 41–64 | 13/94 | 13.8 | 0.829 | 0.460–1.496 | 0.534 |
| 65–84 | 767/5055 | 15.2 | 0.943 | 0.859–1.036 | 0.221 |
| 85–110 | 1717/11,156 | 15.4 | Refa | ||
| Gender | |||||
| Women | 1613/11,031 | 14.6 | 0.876 | 0.799–0.960 | 0.005 |
| Men | 884/5274 | 16.8 | Refa | ||
a Reference
Logistic regression model comparing the probability of receiving fluids via enteral tube or intravenously during the last 24 h of life for three age groups (in years) and for men and women, including only hospital deaths, not adjusted for place of death. Odds ratios (OR) and 95% confidence intervals (CI) are reported
| n | % | OR | 95% CI | ||
|---|---|---|---|---|---|
| Fluids via enteral tube or intravenously during the last 24 h of life | |||||
| Age | |||||
| 41–64 | 5/8 | 62.5 | 2.715 | 0.641–11.498 | 0.175 |
| 65–84 | 140/406 | 34.5 | 0.856 | 0.653–1.124 | 0.264 |
| 85–110 | 199/529 | 37.6 | Refa | ||
| Gender | |||||
| Women | 145/419 | 34.6 | 0.851 | 0.650–1.115 | 0.241 |
| Men | 199/524 | 38.0 | Refa | ||
a Reference